Literature DB >> 11717374

Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

N D Volkow1, L Chang, G J Wang, J S Fowler, D Franceschi, M Sedler, S J Gatley, E Miller, R Hitzemann, Y S Ding, J Logan.   

Abstract

Methamphetamine is a popular drug of abuse that is neurotoxic to dopamine (DA) terminals when administered to laboratory animals. Studies in methamphetamine abusers have also documented significant loss of DA transporters (used as markers of the DA terminal) that are associated with slower motor function and decreased memory. The extent to which the loss of DA transporters predisposes methamphetamine abusers to neurodegenerative disorders such as Parkinsonism is unclear and may depend in part on the degree of recovery. Here we assessed the effects of protracted abstinence on the loss of DA transporters in striatum, in methamphetamine abusers using positron emission tomography and [(11)C]d-threo-methylphenidate (DA transporter radioligand). Brain DA transporters in five methamphetamine abusers evaluated during short abstinence (<6 months) and then retested during protracted abstinence (12-17 months) showed significant increases with protracted abstinence (caudate, +19%; putamen, +16%). Although performance in some of the tests for which we observed an association with DA transporters showed some improvement, this effect was not significant. The DA transporter increases with abstinence could indicate that methamphetamine-induced DA transporter loss reflects temporary adaptive changes (i.e., downregulation), that the loss reflects DA terminal damage but that terminals can recover, or that remaining viable terminals increase synaptic arborization. Because neuropsychological tests did not improve to the same extent, this suggests that the increase of the DA transporters was not sufficient for complete function recovery. These findings have treatment implications because they suggest that protracted abstinence may reverse some of methamphetamine-induced alterations in brain DA terminals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717374      PMCID: PMC6763886     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

Review 1.  Neurotoxic amphetamine analogues: effects in monkeys and implications for humans.

Authors:  G A Ricaurte; U D McCann
Journal:  Ann N Y Acad Sci       Date:  1992-05-11       Impact factor: 5.691

2.  Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning.

Authors:  B Bendriem; S L Dewey; D J Schlyer; A P Wolf; N D Volkow
Journal:  IEEE Trans Med Imaging       Date:  1991       Impact factor: 10.048

3.  Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain.

Authors:  Y Zhang; J A Angulo
Journal:  Synapse       Date:  1996-11       Impact factor: 2.562

4.  Long-term effects of chronic methamphetamine administration in rhesus monkeys.

Authors:  W L Woolverton; G A Ricaurte; L S Forno; L S Seiden
Journal:  Brain Res       Date:  1989-05-01       Impact factor: 3.252

5.  Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss.

Authors:  D C Harvey; G Lacan; S P Tanious; W P Melega
Journal:  Brain Res       Date:  2000-07-21       Impact factor: 3.252

6.  Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.

Authors:  D B Miller; J P O'Callaghan; S F Ali
Journal:  Ann N Y Acad Sci       Date:  2000-09       Impact factor: 5.691

7.  Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine.

Authors:  W A Cass; M W Manning
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

8.  Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity.

Authors:  S D Friedman; E Castañeda; G K Hodge
Journal:  Pharmacol Biochem Behav       Date:  1998-09       Impact factor: 3.533

9.  Methamphetamine-induced depression of tryptophan hydroxylase: recovery following acute treatment.

Authors:  C Bakhit; J W Gibb
Journal:  Eur J Pharmacol       Date:  1981-12-03       Impact factor: 4.432

10.  Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data.

Authors:  J Logan; N D Volkow; J S Fowler; G J Wang; S L Dewey; R MacGregor; D Schlyer; S J Gatley; N Pappas; P King
Journal:  J Cereb Blood Flow Metab       Date:  1994-11       Impact factor: 6.200

View more
  251 in total

1.  Altered learning and Arc-regulated consolidation of learning in striatum by methamphetamine-induced neurotoxicity.

Authors:  Elissa D Pastuzyn; David E Chapman; Karen S Wilcox; Kristen A Keefe
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

Review 2.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 3.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

4.  Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study.

Authors:  Ruth Salo; Michael H Buonocore; Martin Leamon; Yutaka Natsuaki; Christy Waters; Charles D Moore; Gantt P Galloway; Thomas E Nordahl
Journal:  Drug Alcohol Depend       Date:  2010-08-23       Impact factor: 4.492

5.  The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.

Authors:  Kimber L Price; Stacia M DeSantis; Annie N Simpson; Bryan K Tolliver; Aimee L McRae-Clark; Michael E Saladin; Nathaniel L Baker; Mark T Wagner; Kathleen T Brady
Journal:  Am J Addict       Date:  2011-07-18

6.  Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.

Authors:  Winnie Jeng; Peter G Wells
Journal:  ACS Chem Neurosci       Date:  2010-02-23       Impact factor: 4.418

7.  Elevated neurobehavioral symptoms are associated with everyday functioning problems in chronic methamphetamine users.

Authors:  Jordan E Cattie; Steven Paul Woods; Jennifer E Iudicello; Carolina Posada; Igor Grant
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

8.  Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals.

Authors:  Jennifer L Stewart; Colm G Connolly; April C May; Susan F Tapert; Marc Wittmann; Martin P Paulus
Journal:  Addiction       Date:  2013-12-15       Impact factor: 6.526

9.  Effect of methamphetamine neurotoxicity on learning-induced Arc mRNA expression in identified striatal efferent neurons.

Authors:  David P Daberkow; Matthew D Riedy; Raymond P Kesner; Kristen A Keefe
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 10.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.